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a b s t r a c t
According to the CDC, the most common type of heart disease is coronary artery disease, which
commonly leads to myocardial infarction (MI). Therapeutic approaches to lessen the resulting cardio-
vascular injury associated with MI are limited. Recently, MicroRNAs (miRNAs) have been shown to act as
negative regulators of gene expression by inhibiting mRNA translation and/or stimulating mRNA
degradation. A single miRNA can modulate physiological or disease phenotypes by regulating whole
functional systems. Importantly, miRNAs can regulate cardiac function, thereby modulating heart muscle
contraction, heart growth and morphogenesis. MicroRNA-499 (miRNA-499) is a cardiac-speciﬁc miRNA
that when elevated causes cardiomyocyte hypertrophy, in turn preventing cardiac dysfunction during MI.
Previous studies revealed that combination treatment with conjugated linoleic acid (cLA) and nitrite
preserved cardiovascular function in mice. Therefore, it was hypothesized that cLA and nitrite may
regulate miRNA-499, thus providing cardiac protection during MI. To test this hypothesis, 12-week old
mice were treated with cLA (10 mg/kg/d-via osmotic mini-pump) or cLA and nitrite (50 ppm-drinking
water) 3 days prior to MI (ligation of the left anterior descending artery). Echocardiography and
pressure–volume (PV)-loop analysis revealed that cLA and nitrite-treated MI mice had improved heart
function (10 days following MI) compared to untreated MI mice. Treatment with cLA and nitrite
signiﬁcantly induced levels of miRNA-499 compared to untreated MI mice. In addition, treatment with
cLA and nitrite abolished MI-induced protein expression of p53 and dynamin-related protein-1 (DRP-1).
Moreover, the antioxidant enzyme expression of heme oxygenase-1 (HO-1) was elevated in MI mice
treated with cLA and nitrite compared to untreated MI mice. Confocal imaging on heart tissue conﬁrmed
expression the levels of HO-1 and p53. Taken together, these results suggest that therapeutic treatment
with cLA and nitrite may provide signiﬁcant protection during MI through regulation of both cardiac
speciﬁc miRNA-499 and upregulation of phase 2 antioxidant enzyme expression.
& 2013 The Authors. Published by Elsevier B.V. All rights reserved.
Introduction
Myocardial infarction (MI) affects over ﬁve million individuals
in the US and remains a signiﬁcant and yet unsolved health
problem. Experimental MI in mice is an important disease model,
in part due to the ability to study genetic manipulations. Addi-
tionally, surgical induction of MI allows precise timing and loca-
tion of a coronary event [1]. MI results in an insufﬁcient blood
supply to cardiac tissue, which leads to myocardial inﬂammation
followed by scar formation at the site of infarction, as well as
changes in the non-infarcted myocardium [2–4].
MI is characterized by signiﬁcant changes in gene expression,
many of which represent adaptive or maladaptive responses to stress
[5–9]. The resulting cardiac stress induces rapid changes in gene
expression immediately following MI [10]. Cardiomyocyte cell death
is a consequence of myocardial injury, which occurs as early as the
initiation of acute MI [11]. Cardiomyocyte death or apoptosis is a key
factor in transition from cardiac hypertrophy to heart failure [12]. p53
is a well-known transcription factor which mediates apoptosis by
activating the manifestation of pro-apoptotic genes [13]. Previous
studies have demonstrated that p53 activity is enhanced during MI
and that p53 plays a critical role in the regulation of hypoxia-induced
apoptosis of cardiomyocytes [14,15]. Thus, p53 becomes an impor-
tant therapeutic target, with regard to attenuation of cardiac apop-
tosis and consequent heart failure.
MicroRNAs quantitatively regulate mature-RNAs, which affect
the cardiac transcriptional output and cardiac function [16]. Micro-
RNAs (miRNAs) are endogenous, single-stranded non-coding RNAs
ranging 18 to 24 nucleotides in length, that play an important role
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in gene regulation [16,17]. In screening for miRNAs enriched in the
heart, we found an abundant miRNA, miRNA-499, which is an
evolutionarily conserved muscle-speciﬁc microRNA that is encoded
within the intron of myosin heavy chain and is highly expressed in
the cardiac ventricles [16–18]. Plasma miRNA-499 is known as a
biomarker of acute MI, as plasma miR-499 has been observed in
individuals with MI [19].
Studies have shown that diets with diversiﬁed fats may be an
effective strategy in decreasing risk of cardiovascular disease
(CVD) [20,21]. Conjugated linoleic acid (cLA) is a fatty acid that
occurs as a mixture of positional and geometric isomers of linoleic
acid (LA), which is produced in ruminant animals via an enzymatic
isomerase reaction [22]. cLA contains 18 carbon atoms with two
conjugated double bonds separated by a single bond [23]. cLA is
found naturally in food products from these animals predomi-
nantly as the cis-9,trans-11 form, whereas synthetic cLA prepara-
tions consist of a few different isomers with an approximately
equal amount of cis-9,trans-11 and trans-10,cis-12 cLA [21,24].
Select modiﬁed fatty acids, such as nitrated fatty acids are known
to induce pleuripotent anti-inﬂammatory effects [25]. Recent lit-
erature suggests that dietary cLA and nitrite supplementation in
rodents elevates NO2-cLA levels in the plasma and tissues, inducing
heme oxygenase-1 (HO-1) expression in the target tissue [26].
HO-1 catalyzes the oxidation of heme—producing biliverdin, iron,
and carbon monoxide (CO) [27,28]. Importantly, biliveridin is
converted to bilirubin, a known potent antioxidant. Additionally,
iron can be sequestered by ferritin, leading to off target anti-
apoptotic effects and carbon monoxide has similar characteristics
to nitric oxide, facilitating numerous biological functions including
anti-inﬂammatory effects [28–30].
Ultimately, heart function is highly dependent on ATP genera-
tion. The heart is enriched with mitochondria that provide the
energy required for cardiomyocyte function [31]. Therefore, it is
known that mitochondria play a critical role in development and
progression of many cardiac diseases such as hypertrophy and
myocardial infarction. Previous studies suggest that mitochondria
are highly dynamic and that changes in mitochondrial shape can
affect a variety of biological processes such as apoptosis and
ﬁbrosis [32,33]. Mitochondria are dynamic organelles, which
constantly undergo ﬁssion and fusion [32–34]. These two oppos-
ing processes are regulated by the mitochondrial ﬁssion proteins
mitofusin and the mitochondrial ﬁssion proteins Drp-1 [31].
During apoptosis, Drp-1 foci accumulates on mitochondria and
can enhance mitochondrial ﬁssion [35,36].
In the present study an in vivo model of MI is used to further
elucidate the possible mechanism whereby combination treat-
ment with cLA and nitrite is cardioprotective. Herein we demon-
strate that cLA and nitrite signiﬁcantly induced levels of miR-499
in heart compared to untreated MI mice. Additionally, co-treatment
signiﬁcantly reduced levels of p53 expression and induced expres-
sion of HO-1. These results suggest that treatment with cLA and
nitrite may provide signiﬁcant protection during MI through
regulation of cardiac speciﬁc miRNA and upregulation of phase
2 antioxidant enzyme expression.
Materials and methods
Animals
Mice were fed standard chow and water ad libitum. All animal
procedures were reviewed and approved by an independent
Institutional Animal Care and Use Committee of the University of
Louisville, School of Medicine. In addition, all studies were
performed in accordance with animal care and use guidelines of
the National Institutes of Health.
Mouse model of myocardial infarction
Male C57BL/6 mice, 10- to 12-wks old, were anesthetized with
isoﬂurane, intubated and ventilated with CWE advanced ventilator
(Webster, TX). Body temperature was maintained with an Indus
Temperature feedback/surgical table and ECG system. Aseptic
procedure was used for preparation of the surgical site through
scrubbing with a 0.8% chlorhexidine solution. A left thoracotomy
was performed via the fourth intercostal space and the lungs
retracted to expose the heart. After opening the pericardium, the
left anterior descending (LAD) coronary artery was ligated with an
8–0 silk suture near its origin between the pulmonary outﬂow
tract and the edge of the atrium. Ligation was deemed successful
when the anterior wall of the left ventricle (LV) turned pale. The
lungs were inﬂated by increasing positive end-expiratory pressure,
and the thoracotomy side was closed in layers. The lungs were re-
expanded, and the chest was closed. The animals were removed
from the ventilator and allowed to recover on a heating pad. Mice
were checked daily for signs of pain or distress and buprenex at
0.05 mg/kg SQ is given before and every 12 h for 48 h. Mice were
treated with cLA (10 mg/kg/d-via osmotic mini-pump) or cLA and
nitrite (50 ppm-drinking water) 3 days prior to ligation of the LAD
artery.
In vivo hemodynamic measurements
Isoﬂurane was used to anesthetize the mouse and conductance
readings were made for 15–20 min, prior to harvesting heart
tissue. Brieﬂy, the mouse was placed in a supine position on a
37 1C pad under the surgical microscope and the limbs were
restrained with tape. A 0.5 cm skin incision was performed in the
right neck area and the carotid artery was isolated using silk sutures.
The cranial aspect of the carotid artery was ligated and a micro-
surgical clip was placed on the proximal carotid artery for hemos-
tasis. An arteriotomy was performed with microsurgical scissors, and
a 1.2 French conductance catheter (Transonic, London, ON, Canada)
was introduced into the carotid artery and advanced retrograde
across the aortic valve into the left ventricle. The catheter was
advanced under continuous hemodynamic monitoring to issue
proper placement in the left ventricle (LV). The catheter was secured
within the carotid artery with the proximal suture. LV pressure–
volume loops were recorded in the steady state. Loops were recorded
using the iWorks data acquisition software package, and analyzed
using the LabScribe2 pressure–volume data analysis software pack-
age (iWorks, St. Albans, Vermont).
Real-time quantitative PCR
Total heart tissue was homogenized in TRIzol and RNA was
isolated, as previously described [37]. Complimentary DNA was
synthesized using oligo (dT) primers (Promega Corporation, Madison,
WI) and stored at 80 1C until experiments were performed. Reac-
tions were done using 2000 ng/mL cDNA and SYBR Green Master Mix
(BioRad Laboratories, Hercules, CA). BioRad CFX Manager (BioRad
Laboratories, Hercules, CA) software was used to analyze results. Gene
expression was normalized with mRNA expression of 18S. Samples
were analyzed in triplicate using N¼3 for each independent experi-
ment. The following primer sequences were used:
murine pre-miR-499
Forward-1: 5′-GGGCAGCTGTTAAGACTTGC-3′
Forward-2: 5′-TGGCTTTCTGCAGGCTGC-3′
Reverse: 5′-AGGCAGCAGCACAGACTTG-3′
murine miR-499
Forward: 5′-GGG-TGG-GCA-GCT-GTT-AAG-AC-3′
Reverse: 5′-AGG-CAG-CAG-CAC-AGA-CTT-G-3′
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murine DRP-1
Forward: 5′-AAA CTC CTA TCA CGC TCA TCA-3′
Reverse: 5′-CTC ATC CTC CAC GCA TCC T-3′
Western blot analysis
Heart tissue homogenate (100 μg) was electrophoresed using
SDS-PAGE method as previously described [38,39]. Afﬁnity pur-
iﬁed GAPDH (1:3000) (Trevigen, Gaithersburg, MD) p53 (1:1000)
(Calbiochem, Billerica, MA) and HO-1 (1:1000) (Stressgen Bio-
technologies, Farmingdale, NY) antibodies were detected using
specie-appropriate horse radish peroxidase-labeled secondary
antibodies.
Histology and confocal microscopy
Hearts were collected from the mice and thoroughly washed in
PBS. Using Peel-A-Way disposable plastic tissue embedding molds
(Polysciense Inc, Washington, PA) ﬁlled with tissue freezing media
(Triangle Biomedical Sciences, Durham, NC), hearts were pre-
served and stored at 80 1C until analysis. Tissue sections (5 mm
in thickness) were made using Leica CM 1850 Cryocut microtome
(Bannockburn, IL, USA). Sections were placed on super frost plus
glass slides, air-dried, and processed for Immunohistochemistry
(IHC) staining.
Immunohistochemistry
Immunohistochemistry and laser-scanning confocal micro-
scopy were used to visualize MI-induced changes in p53 and
HO-1 expression and localization. Immunohistochemistry was
performed on frozen tissue sections using a standard IHC protocol.
Primary antibodies were applied overnight (anti-p53, Calbiochem,
Billerica, MA and anti HO-1, Stressgen Biotechnologies, Farming-
dale, NY). Secondary antibodies labeled with Alexa Fluor 488 and
Alexa Fluor 568 (Invitrogen, Carlsbad, CA) were applied for protein
immunodetection. Stained slides were analyzed for ﬂuorescence
using a laser scanning confocal microscope (Olympus FluoView-
1000, objective 40X) set at the appropriate ﬁlter settings. The total
ﬂuorescence (green or red) intensity in 5 random ﬁelds (for each
experimental sample) was measured with image analysis software
(Image-Pro Plus, Media Cybernetics). Fluorescence intensity values
for each experimental group were averaged and presented as
ﬂuorescent intensity units (FIU).
Statistical analysis
Values are presented as mean7SD. Differences between
groups were tested by one-way ANOVA and Bonferroni's multiple
comparison post hoc analysis. Data was considered statistically
signiﬁcant for po0.05.
Results
Co-treatment of cLA and nitrite increases heart weight following MI
Hearts isolated from MI (10 days) and treated mice were found to
be enlarged, with ventricular dilatation (Fig. 1A). The heart weight/
tibia length ratio was signiﬁcantly increased in MI and single treated
mice compare to control hearts, where co-administration cLA and
nitrite was signiﬁcantly higher than MI hearts with or without single
treatment (Fig. 1A). There was no signiﬁcant difference in body
weight/tibia length ratio in all the group of mice (Fig. 1B).
Heart weight (HW)
Co
ntr
ol MI
Co
ntr
ol+
cL
A
MI
+c
LAC
on
tro
l+NMI
+N
Co
ntr
ol+
cL
A+
N
MI
+c
LA
+N
0
50
100
150
H
W
/T
ib
ia
 L
en
gt
h,
 m
g/
cm
Co
ntr
ol MI
Co
ntr
ol+
cL
A
MI
+c
LA
Co
ntr
ol+
N
MI
+N
Co
ntr
ol+
cL
A+
N
MI
+c
LA
+N
0
5
10
15
20
Body Weight (BW)
B
W
/T
ib
ia
 L
en
gt
h,
 g
/c
m
Fig. 1. Co-treatment with cLA and nitrite increases heart weight following MI. Heart weight is signiﬁcantly increased following cLA or nitrite with MI, or in MI alone (A). cLA
and nitrite co-treatment results in a further increase in heart weight, which is signiﬁcant compared to MI alone (A) (npo0.05 to control), #po0.05 to MI, n¼8), where
overall body weight is unchanged (B).
Table 1
Hemodynamics of MI and control mice based on pressure–volume. All values are expressed as mean7S.D. ESP, end-systolic pressure; EDP, end-diastolic pressure; SV, stoke
volume; EF, ejection fraction; CO, cardiac output; BPM, beats per minute; Signiﬁcance is designated as follows: npo0.05, compared to control, #po0.05 compared to MI and
n#po0.05 compared to control and MI, ∧po0.05 compared to MIþcLAþN, where n¼6 for each group.
HR ESP EDP ESV EDV SV CO EF
BPM mmHg mmHg mL mL mL mL/min %
Control 552.0071.79 80.8870.49 6.9570.67 15.4370.37 40.6671.72 25.2371.53 13926.937449.70 62.0572.13
MI 555.7878.67 78.3673.72 2.7371.25∧ 55.4373.72n 72.7772.40n 17.6673.72n 9800.1971218.05n 23.0074.17n
MIþcLA 546.8274.30 79.8079.78 2.8372.55∧ 60.9072.34n 75.4070.47n 14.5172.19n 7644.8271008.05n 19.6671.88n
MIþN 538.98712.14 75.7570.85 3.7770.10 59.2174.57n 75.4673.89n 16.2371.93n 8608.7471898.04n 21.3572.46n
MIþcLAþN 556.8274.30 85.7970.75 10.2673.26 30.9072.34n# 56.9072.34n# 26.5672.36# 14767.3671121.31# 45.4272.13n#
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cLA and nitrite co-treatment improves cardiac function after MI
MI is characterized by ventricular chamber dilation and dys-
function (Table 1). We observed a signiﬁcant rightward shift of the
PV loop in MI and single treated mice (Fig. 2). Chamber dilation
also resulted in signiﬁcant increase in both end-systolic and end-
diastolic volume (Fig. 2, Table 1). As shown in Fig. 2, invasive
hemodynamic measurements showed a reduction in EF in MI vs.
the control groups (Fig. 2, Table 1). Treatment did not change EF in
control animals (Fig. 2, Table 1). However, co-administration with
cLA and nitrite shifted PV-loop to the left compared to MI PV-loop,
indicating that the overall heart function is improved in cLA and
nitrite-treated mice following MI.
Mitochondrial ﬁssion factor DRP-1 is signiﬁcantly increased in mice
following MI
MI caused a robust increase in Drp-1 expression in MI (Fig. 3).
Individual treatments with cLA or nitrite increased expression of
Drp-1 compared to control mice, but the expression was overall
lower than with MI-induction (Fig. 3). Co-treatment with cLA and
nitrite attenuated Drp-1 expression in MI mice (Fig. 3).
Co-treatment of cLA and nitrite regulates pre miRNA-499 and miRNA-
499 during MI
To investigate the speciﬁc role of miRNA-499 in regulation of
cardiomyocyte hypertrophy during MI, miRNA-499 levels were
measured in the heart (Fig. 4). Both pre-miRNA-499 and miRNA-
499 are increased following MI with combination treatment of cLA
and nitrite (Fig. 4). There were no signiﬁcant differences in single
treated MI mice or with MI alone (Fig. 4).
cLA and nitrite treatment attenuates p53 expression following MI
Expression of p53 was deﬁned by immunohistochemical stain-
ing of cryo-sectioned hearts (Fig. 5A). To support the immunohis-
tochemical results that miRNA-499 blocks p53 after co-
administration treatment with cLA and nitrite during MI, the level
of p53 was assessed by Western blot analysis (Fig. 5). The protein
level of p53 was increased following MI and in single treated mice,
but was abolished after co-treatment with cLA and nitrite (Fig. 5B
and D). The p53 staining support the data obtained via Western
blot analysis.
HO-1 expression increases in MI following cLA and nitrite treatment
HO-1 expression is increased, as demonstrated using immuno-
histochemical staining of cryo-sectioned heart tissue (Fig. 5A).
To support the hypothesis that co-treatment with cLA and nitrite
during MI induces HO-1 level, the expression of HO-1 was
assessed using Western blot analysis (Fig. 5). Following treatment
with cLA and nitrite, HO-1 protein expression is signiﬁcantly
increased (Fig. 5C and D).
Discussion
This study examines the effects of cLA with and without nitrite
supplementation on cardiovascular injury following MI. Consider-
ing the initiative to replace saturated fats with so-called ‘healthy
fats', to promote overall weight loss and maintenance, the health
effects of fats such as cLA require investigation. The principal
ﬁndings demonstrated here, are that cLA is not protective in MI,
but instead worsens cardiac injury. However, supplementation
with nitrite in cLA-(10 mg/kg/d-via osmotic mini-pump) treated
mice, leads to cardioprotection in MI injury. Speciﬁcally, cLA and
nitrite co-treatment signiﬁcantly increases miRNA499 and blocks
mitochondrial ﬁssion through inhibition of p53. Further, co-
treatment with cLA and nitrite also induces HO-1 protein expres-
sion, which supports cardioprotection in this MI model. Overall,
cLA and nitrite mediate protection and result in improved heart
function in this murine model of MI.
It is known that mitochondria undergo ﬁssion and fusion events
continuously in non-disease states [40]. Mitochondrial morpholo-
gical dynamics affect the outcome of ischemic heart damage and
pathogenesis [40]. The Drp1 protein plays an important role in
ﬁssion, regulating mitochondrial membrane dynamics [34,40,41].
Drp1 exists as small oligomers, located primarily at the mitochon-
drial outer membrane. These oligomers can connect to each other,
forming larger multimeric structures, thus mediating mitochondrial
division [5,34,41,42]. In previous studies Drp1 has been identiﬁed as
a mediator of mitochondrial morphological changes and cell death
during cardiac ischemic injury [42]. It has been reported that miR-
499 affects DRP-1 mediated apoptosis and the severity of MI and
cardiac dysfunction during heart disease [18]. Our data suggest that
MI signiﬁcantly increases Drp1 expression in the heart of cLA-
and nitrite-treated, as well as in non-treated mice (Fig. 3). Drp1
Control MI+cLA+N MI MI+cLA
MI+N
Fig. 2. Co-treatment with cLA and nitrite signiﬁcantly improves cardiac function
after MI. Treatment with cLA exacerbates cardiac injury after MI, where combina-
tion treatment (supplementation with nitrite) rescues heart function following MI
(npo0.05 to control, #po0.05 to MI, n¼8).
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Fig. 3. Mitochondrial ﬁssion factor DRP-1 is attenuated in mice treated with cLA
and nitrite following MI. Nitrite- or cLA-treated MI mice have decreased levels of
DRP-1 compared to MI alone. Combination treatment with cLA and nitrite
signiﬁcantly lowers the level of Drp-1 in MI mice, comparable to control values
(npo0.05 to control, #po0.05 to MI).
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Fig. 4. Co-treatment with cLA and nitrite increases pre-miRNA-499 and miRNA-499 during MI. Pre-miRNA-499 (A) and miRNA-499 (B) is increased in MI mice after
combination treatment with cLA and nitrite (npo0.05).
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Fig. 5. Co-treatment with cLA and nitrite attenuates p53 and induces HO-1 expression following MI. Confocal microscopy (A): heart tissue was labeled with p53 (green),
HO-1 (red), and cell nuclei was labeled with DAPI (blue). Western blot analysis reveals that p53 is signiﬁcantly increased in cardiac tissue following MI (B). Quantitated
protein expression reveals that co-administration of cLA and nitrite lowers p53 levels, while increasing expression of HO-1 (C) and (D) (npo0.05). (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
N. Qipshidze-Kelm et al. / Redox Biology 2 (2014) 1–7 5
expression was abolished following co-treatment with cLA and
nitrite in MI mice.
There is evidence that miRNA-499 controls the apoptotic
pathway thorough regulation of p53 [18]. Our data supports the
hypothesis that miRNA-499 decreases Drp1 levels after combina-
tion treatment with cLA and nitrite. Myocardial infarction is
known to cause cardiomyocyte ischemia, in turn, leading to p53-
dependent cardiomyocyte apoptosis [14,43]. The current study
extends previous ﬁndings by demonstrating that ischemia causes
increased expression of p53 following MI in non-treated and cLA-
or nitrite-treated mice and provides signiﬁcant implications with
regard to the molecular mechanism of cardiomyocyte apoptosis
following myocardial infarction.
Previous studies have shown that pharmacological delivery of
nitrated fatty acids lead to protection of cardiovascular injury
[44,45]. These studies have focused on protective signaling path-
ways including inhibition of p65 subunit of NFκB and increased
expression of HO-1. In a model of stenosis femoral artery injury,
nitrated oleic acid induced vascular expression of HO-1, mediating
protection against neointimal hyperplasia [45]. Nitrated oleic
acid inhibited activation of NFκB in a murine model of ischemia
reperfusion injury, resulting in reduction of infarct size [44]. More
recent data suggests that dietary cLA is a privileged substrate for
nitration reactions facilitated by mitochondria, digestion, and macro-
phage activation and following metabolic stress such as MI [26].
Co-administration of dietary cLA and nitrite supplementation raises
NO2cLA levels in plasma and tissues, which in turn induces HO-1
expression in target organs [26].
In the failing heart, HO-1 has anti-apoptotic effects by attenuating
cell loss, p53 expression, and pathological heart remodeling [30].
Cytoprotective effects of HO-1 are mediated by reaction products CO
and biliverdin. Importantly, biliveridin is converted to bilirubin, a
known potent antioxidant [30,46]. Previous studies have shown
induction of HO-1 to result in cardiac protection during ischemia/
reperfusion injury [30,47–49]. Our results establish that the upregu-
lation of HO-1 during co-treatment with cLA and nitrite in MI,
ameliorates cardiac dysfunction. Further, sustained HO-1 expression
in MI mice treatment with cLA and nitrite promotes miRNA-499
expression and limits Drp1and p53 expression.
Overall, these data reveal links among p53, HO-1, miR-499, and
Drp1 with regard to regulation of the apoptotic program pro-
gramed cell death in the heart. Taken together, these results
suggest that therapeutic treatment with cLA and nitrite may
provide cardiac protection during MI through the regulation of
both cardiac speciﬁc miR-499, as well as induction of cardiac HO-1
expression. Further, this data suggests that modulation of miR-499
may represent a therapeutic approach to treat apoptosis-related
cardiac disease, including MI.
Acknowledgements
Research reported in this publication was supported by NIH
K99/R00HL95769 to MPC. The content herein is solely the respon-
sibility of the authors and does not necessarily represent the
ofﬁcial views of the National Institutes of Health. The authors also
acknowledge ongoing support from the University of Louisville.
References
[1] R. Klocke, W. Tian, M.T. Kuhlmann, S. Nikol, Surgical animal models of heart
failure related to coronary heart disease, Cardiovasc. Res. 74 (2007) 29–38.
[2] M. Hori, K. Nishida, Oxidative stress and left ventricular remodelling after
myocardial infarction, Cardiovasc. Res. 81 (2009) 457–464.
[3] U. Landmesser, K.C. Wollert, H. Drexler, Potential novel pharmacological
therapies for myocardial remodelling, Cardiovasc. Res. 81 (2009) 519–527.
[4] Y. Sun, Myocardial repair/remodelling following infarction: roles of local
factors, Cardiovasc. Res. 81 (2009) 482–490.
[5] L. Choong-Chin, J.D. Victor, Molecular genetics and genomics of heart failure,
Nat. Rev. Genet. 5 (2004) 811–825.
[6] B.D. Lowes, E.M. Gilbert, W.T. Abraham, W.A. Minobe, P. Larrabee, D. Ferguson,
E.E. Wolfel, J. Lindenfeld, T. Tsvetkova, A.D. Robertson, R.A. Quaife, M.
R. Bristow, Myocardial gene expression in dilated cardiomyopathy treated
with beta-blocking agents, N. Engl. J. Med. 346 (2002) 1357–1365.
[7] S. Kaab, A. Barth, D. Margerie, M. Dugas, M. Gebauer, L. Zwermann, S. Merk,
A. Pfeufer, K. Steinmeyer, M. Bleich, E. Kreuzer, G. Steinbeck, M. Näbauer,
Global gene expression in human myocardium—oligonucleotide microarray
analysis of regional diversity and transcriptional regulation in heart failure,
J. Mol. Med. 82 (2004) 308–316.
[8] A.S. Barth, R. Kuner, A. Buness, M. Ruschhaupt, S. Merk, L. Zwermann, S. Kääb,
E. Kreuzer, G. Steinbeck, U. Mansmann, A. Poustka, M. Nabauer, H. Sültmann,
Identiﬁcation of a common gene expression signature in dilated cardiomyo-
pathy across independent microarray studies, J. Am. Coll. Cardiol. 48 (2006)
1610–1617.
[9] M. Movassagh, M.-K. Choy, M. Goddard, M.R. Bennett, T.A. Down, R.S.Y. Foo,
Differential DNA methylation correlates with differential expression of angio-
genic factors in human heart failure, PLoS One 5 (2010) e8564.
[10] S. Izumo, B. Nadal-Ginard, V. Mahdavi, Protooncogene induction and repro-
gramming of cardiac gene expression produced by pressure overload, Proc.
Nat. Acad. Sci. 85 (1988) 339–343.
[11] V.P.M. van Empel, A.T.A. Bertrand, L. Hofstra, H.J. Crijns, P.A. Doevendans,
L.J. De Windt, Myocyte apoptosis in heart failure, Cardiovasc. Res. 67 (2005)
21–29.
[12] D. Wencker, M. Chandra, K. Nguyen, W. Miao, S. Garantziotis, S.M. Factor,
J. Shirani, R.C. Armstrong, R.N. Kitsis, A mechanistic role for cardiac myocyte
apoptosis in heart failure, J. Clin. Invest. 111 (2003) 1497–1504.
[13] S.F. Jordan, W.L. Scott, Control of apoptosis by p53, Oncogene 22 (2003)
9030–9040.
[14] X. Long, M.O. Boluyt, M.L. Hipolito, M.S. Lundberg, J.S. Zheng, L. O'Neill,
C. Cirielli, E.G. Lakatta, M.T. Crow, p53 and the hypoxia-induced apoptosis of
cultured neonatal rat cardiac myocytes, J. Clin. Invest. 99 (1997) 2635–2643.
[15] M.T. Crow, K. Mani, Y.-J. Nam, R.N. Kitsis, The mitochondrial death pathway
and cardiac myocyte apoptosis, Circ. Res. 95 (2004) 957–970.
[16] J.T.C. Shieh, Y. Huang, J. Gilmore, D. Srivastava, Elevated miR-499 levels blunt
the cardiac stress response, PLoS One 6 (2011).
[17] H. Zhu, G.-C. Fan, Role of microRNAs in the reperfused myocardium towards
post-infarct remodelling, Cardiovasc. Res. 94 (2012) 284–292.
[18] J.X. Wang, J.Q. Jiao, Q. Li, B. Long, K. Wang, J.P. Liu, Y.R. Li, P.F. Li, miR-499
Regulates mitochondrial dynamics by targeting calcineurin and dynamin-
related protein-1, Nat. Med. 17 (2011) 71–78.
[19] T. Adachi, M. Nakanishi, Y. Otsuka, K. Nishimura, G. Hirokawa, Y. Goto,
H. Nonogi, N. Iwai, Plasma MicroRNA 499 as a biomarker of acute myocardial
infarction, Clin. Chem. 56 (2010) 1183–1185.
[20] M.J. Stampfer, F.B. Hu, J.E. Manson, E.B. Rimm, W.C. Willett, Primary preven-
tion of coronary heart disease in women through diet and lifestyle, N. Engl. J.
Med. 343 (2000) 16–22.
[21] S.K. Gebauer, J.-M. Chardigny, M.U. Jakobsen, B. Lamarche, A.L. Lock,
S.D. Proctor, D.J. Baer, Effects of ruminant trans fatty acids on cardiovascular
disease and cancer: a comprehensive review of epidemiological, clinical, and
mechanistic studies, Adv. Nutr.: Int. Rev. J. 2 (2011) 332–354.
[22] J.L.C.M van de Vossenberg, K.N. Joblin, Biohydrogenation of C18 unsaturated
fatty acids to stearic acid by a strain of Butyrivibrio hungatei from the bovine
rumen, Lett. Appl. Microbiol. 37 (2003) 424–428.
[23] W. Campbell, M.A. Drake, D.K. Larick, The impact of fortiﬁcation with
conjugated linoleic acid (CLA) on the quality of ﬂuid milk, J. Dairy Sci. 86
(2003) 43–51.
[24] M.W. Pariza, Y. Park, M.E. Cook, The biologically active isomers of conjugated
linoleic acid, Prog. Lipid Res. 40 (2001) 283–298.
[25] B.A. Freeman, P.R.S. Baker, F.J. Schopfer, S.R. Woodcock, A. Napolitano,
M. d'Ischia, Nitro-fatty acid formation and signaling, J. Biol. Chem. 283
(2008) 15515–15519.
[26] G. Bonacci, P.R.S. Baker, S.R. Salvatore, D. Shores, N.K.H. Khoo, J.R. Koenitzer,
D.A. Vitturi, S.R. Woodcock, F. Golin-Bisello, M.P. Cole, S. Watkins, C. St. Croix,
C.I. Batthyany, B.A. Freeman, F.J. Schopfer, Conjugated linoleic acid is a
preferential substrate for fatty acid nitration, J. Biol. Chem. 287 (2012)
44071–44082.
[27] S.W. Ryter, J. Alam, A.M.K. Choi, Heme oxygenase-1/carbon monoxide: from
basic science to therapeutic applications, Physiol. Rev. 86 (2006) 583–650.
[28] M.D. Maines, The heme oxygenase system: a regulator of second messenger
gases, Annu. Rev. Pharmacol. Toxicol. 37 (1997) 517–554.
[29] A. Paine, B. Eiz-Vesper, R. Blasczyk, S. Immenschuh, Signaling to heme
oxygenase-1 and its anti-inﬂammatory therapeutic potential, Biochem. Phar-
macol. 80 (2010) 1895–1903.
[30] G. Wang, T. Hamid, R.J. Keith, G. Zhou, C.R. Partridge, X. Xiang, J.R. Kingery,
R.K. Lewis, Q. Li, D.G. Rokosh, R. Ford, F.G. Spinale, D.W. Riggs, S. Srivastava,
A. Bhatnagar, R. Bolli, S.D. Prabhu, Cardioprotective and antiapoptotic effects
of heme oxygenase-1 in the failing heart, Circulation 121 (2010) 1912–1925.
[31] S.-B. Ong, S. Subrayan, S.Y. Lim, D.M. Yellon, S.M. Davidson, D.J. Hausenloy,
Inhibiting mitochondrial ﬁssion protects the heart against ischemia/reperfu-
sion injury, Circulation 121 (2010).
[32] K.S. Dimmer, L. Scorrano, (De)constructing mitochondria: what for? Physiol-
ogy 21 (2006) 233–241.
N. Qipshidze-Kelm et al. / Redox Biology 2 (2014) 1–76
[33] D.J. Hausenloy, L. Scorrano, Targeting cell death, Clin. Pharmacol. Ther. 82
(2007) 370–373.
[34] H. Chen, D.C. Chan, Mitochondrial dynamics–fusion, ﬁssion, movement, and
mitophagy—in neurodegenerative diseases, Hum. Mol. Gen. 18 (2009).
[35] D.-F. Suen, K.L. Norris, R.J. Youle, Mitochondrial dynamics and apoptosis,
Genes Dev. 22 (2008).
[36] M. Liesa, M. Palacín, A. Zorzano, Mitochondrial dynamics in mammalian
health and disease, Physiol. Rev. (2009).
[37] M.P. Cole, L. Chaiswing, T.D. Oberley, S.E. Edelmann, M.T. Piascik, S.M. Lin,
K.K. Kiningham, D.K. St Clair, The protective roles of nitric oxide and super-
oxide dismutase in adriamycin-induced cardiotoxicity, Cardiovasc. Res. 69
(2006) 186–197.
[38] M.P. Cole, L. Chaiswing, T.D. Oberley, S.E. Edelmann, M.T. Piascik, S.-M. Lin,
K.K. Kiningham, D.K. St. Clair, The protective roles of nitric oxide and super-
oxide dismutase in adriamycin-induced cardiotoxicity, Cardiovasc. Res. 69
(2006) 186–197.
[39] C. Combadière, W. Raoul, X. Guillonneau, F. Sennlaub, Comment on “Ccl2,
Cx3cr1 and Ccl2/Cx3cr1 chemokine deﬁciencies are not sufﬁcient to cause
age-related retinal degeneration” by Luhmann et al. (Exp. Eye Res. 2013; 107:
80.doi: 10.1016), Exp. Eye Res. 111 (2013) 134–135.
[40] C.-R. Chang, C. Blackstone, Dynamic regulation of mitochondrial ﬁssion
through modiﬁcation of the dynamin-related protein Drp1, Ann. N.Y. Acad.
Sci. 1201 (2010) 34–39.
[41] P.-P. Zhu, A. Patterson, J. Stadler, D.P. Seeburg, M. Sheng, C. Blackstone, Intra-
and intermolecular domain interactions of the C-terminal GTPase effector
domain of the multimeric dynamin-like GTPase Drp1, J. Biol. Chem. 279
(2004) 35967–35974.
[42] S. Din, M. Mason, M. Völkers, B. Johnson, C.T. Cottage, Z. Wang, A.Y. Joyo,
P. Quijada, P. Erhardt, N.S. Magnuson, M.H. Konstandin, M.A. Sussman, Pim-1
preserves mitochondrial morphology by inhibiting dynamin-related protein
1 translocation, Proc. Nat. Acad. Sci. 110 (2013) 5969–5974.
[43] M. Kimata, S. Matoba, E. Iwai-Kanai, H. Nakamura, A. Hoshino, M. Nakaoka,
M. Katamura, Y. Okawa, Y. Mita, M. Okigaki, K. Ikeda, T. Tatsumi, H. Matsubara,
p53 and TIGAR regulate cardiac myocyte energy homeostasis under hypoxic
stress, Am. J. Physiol.: Heart Circ. Physiol. 299 (2010) H1908–H1916.
[44] V. Rudolph, T.K. Rudolph, F.J. Schopfer, G. Bonacci, S.R. Woodcock, M.P. Cole,
P.R.S. Baker, R. Ramani, B.A. Freeman, Endogenous generation and protective
effects of nitro-fatty acids in a murine model of focal cardiac ischaemia and
reperfusion, Cardiovasc. Res. 85 (2010) 155–166.
[45] M.P. Cole, T.K. Rudolph, N.K.H. Khoo, U.N. Motanya, F. Golin-Bisello, J.W. Wertz,
F.J. Schopfer, V. Rudolph, S.R. Woodcock, S. Bolisetty, M.S. Ali, J. Zhang,
Y.E. Chen, A. Agarwal, B.A. Freeman, P.M. Bauer, Nitro-fatty acid inhibition of
neointima formation after endoluminal vessel injury, Circ. Res. 105 (2009)
965–972.
[46] L.E. Otterbein, A.M.K. Choi, Heme oxygenase: colors of defense against cellular
stress, Am. J. Physiol.: Lung Cell. Mol. Physiol. 279 (2000) L1029–L1037.
[47] T. Yoshida, N. Maulik, Y.-S. Ho, J. Alam, D.K. Das, Hmox-1, Constitutes an
adaptive response to effect antioxidant cardioprotection: a study with
transgenic mice heterozygous for targeted disruption of the heme
oxygenase-1 gene, Circulation 103 (2001) 1695–1701.
[48] S.-F. Yet, R. Tian, M.D. Layne, Z.Y. Wang, K. Maemura, M. Solovyeva, B. Ith,
L.G. Melo, L. Zhang, J.S. Ingwall, V.J. Dzau, M.-E. Lee, M.A. Perrella, Cardiac-
speciﬁc expression of heme oxygenase-1 protects against ischemia and
reperfusion injury in transgenic mice, Circ. Res. 89 (2001) 168–173.
[49] L.G. Melo, R. Agrawal, L. Zhang, M. Rezvani, A.A. Mangi, A. Ehsan, D.P. Griese,
G. Dell'Acqua, M.J. Mann, J. Oyama, S.-F. Yet, M.D. Layne, M.A. Perrella,
V.J. Dzau, Gene therapy strategy for long-term myocardial protection using
adeno-associated virus-mediated delivery of heme oxygenase gene, Circula-
tion 105 (2002) 602–607.
N. Qipshidze-Kelm et al. / Redox Biology 2 (2014) 1–7 7
